Toronto Public Health seeking person who 'physically handled' bat that may have rabies
Toronto Public Health (TPH) is looking for a person who "physically handled" an injured bat earlier this week that has symptoms of rabies.
The unidentified person came into contact with the bat at the north entrance of 88-100 Harbour Street on Wednesday around 9:20 a.m., the public health agency said in a news release Friday.
TPH said the person is approximately five-feet-eight-inches tall with a beard. They were wearing a black t-shirt, black pants, white sneakers and glasses, and were holding a black water bottle.
The public health agency is asking this person or someone who knows a person who fits this description to immediately contact them or 311.
Rabies is a viral infection that affects the nervous system of mammals, including humans, the release said. It can lead to death if it is left untreated before symptoms appear.
The virus is spread through the saliva of an infected animal, typically entering through a bite or more rarely through a scratch.
"The overall risk of being exposed to rabies in the city is very low, unless direct contact is made with an infected animal's saliva," the news release said.
But people are advised to take preventative measures to reduce their risk of exposure to the virus, such as by staying away from all wild animals, even if they appear tame, injured or sick.
Pet-owners should ensure their pets' rabies vaccinations are up-to-date. They are also encouraged to keep their pets away from wild animals and avoid letting pets roam unsupervised, the news release said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, Wegovy. This decision was made less than two months after the companies had initially announced their collaboration. A healthcare professional holding a device with innovative technology developed by the medical technology company. According to Novo Nordisk, Hims & Hers failed to adhere to the law prohibiting mass sales of compounded drugs under the 'false guise of 'personalization'.' The company accused its partner of disseminating 'deceptive marketing' that risks patient safety and selling 'illegitimate, knockoff versions' of Wegovy. Novo Nordisk states that its investigation showed the active pharmaceutical ingredients (APIs) in these knockoff drugs, particularly 'semaglutide' from telehealth entities and compounding pharmacies, are manufactured by foreign suppliers in China and were often not inspected by the FDA. In response, Andrew Dudum, CEO of Hims & Hers, stated on X that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum alleged that Novo Nordisk's commercial team 'increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.' He asserted that Hims & Hers 'refuse[s] to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice.' Novo Nordisk A/S (NYSE: NVO) is a Danish healthcare company operating globally. It develops, manufactures, and markets pharmaceutical products for the treatment of chronic diseases, primarily diabetes and obesity. Its well-known products include Ozempic, Wegovy, Rybelsus, and Norditropin. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
Judge grants temporary injunction blocking a transgender health-care bill
Advocates fighting to protect access to gender-affirming health care for transgender youth in our province have scored a legal victory. Bill 26 received royal assent in December but hadn't fully come into effect before a judge issued a temporary injunction against the law.
Yahoo
2 hours ago
- Yahoo
Nautilus Biotechnology Leads The Pack In Our Top 3 Penny Stocks
Over the last 7 days, the United States market has risen by 2.7%, and over the past year, it is up by 13%, with earnings expected to grow annually by 15% in the coming years. In light of these conditions, investors might find value in penny stocks—typically smaller or newer companies—that can offer growth opportunities when backed by strong financial health. Though considered a niche area today, penny stocks remain relevant for those seeking potential hidden value and long-term gains; here we explore three such stocks that combine balance sheet resilience with promising prospects. Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.35 $488.24M ★★★★★★ WM Technology (MAPS) $0.9265 $148M ★★★★★★ Tuniu (TOUR) $0.9326 $95.14M ★★★★★★ Safe Bulkers (SB) $3.66 $376.5M ★★★★☆☆ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Flexible Solutions International (FSI) $4.50 $55.08M ★★★★★★ BAB (BABB) $0.8339 $6.1M ★★★★★★ Lifetime Brands (LCUT) $3.77 $86.97M ★★★★★☆ Marine Petroleum Trust (MARP.S) $4.43 $8.76M ★★★★★☆ TETRA Technologies (TTI) $3.46 $441.8M ★★★★☆☆ Click here to see the full list of 449 stocks from our US Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome, with a market cap of approximately $100.09 million. Operations: Nautilus Biotechnology has not reported any revenue segments. Market Cap: $100.09M Nautilus Biotechnology, with a market cap of US$100.09 million, is a pre-revenue life sciences company facing challenges typical of penny stocks. It recently received notice from Nasdaq for not meeting the minimum bid price requirement but has until October 28, 2025, to regain compliance. Despite being debt-free and having short-term assets exceeding liabilities significantly (US$141.6 million vs. US$33.3 million), the company remains unprofitable with losses increasing at an annual rate of 20.5% over five years and no profitability forecast in the near term. Revenue is expected to grow substantially, yet earnings are projected to decline by 8.5% annually over three years. Jump into the full analysis health report here for a deeper understanding of Nautilus Biotechnology. Assess Nautilus Biotechnology's future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: BARK, Inc. is a dog-centric company offering products, services, and content for dogs with a market cap of approximately $144.50 million. Operations: The company's revenue is derived from two primary segments: Commerce, which generated $68.35 million, and Direct to Consumer, contributing $415.84 million. Market Cap: $144.5M BARK, Inc., with a market cap of US$144.50 million, is navigating the challenges typical of penny stocks with a focus on dog-centric products and services. Despite being unprofitable and not expected to achieve profitability in the next three years, BARK has shown financial improvements; its short-term assets exceed both short-term and long-term liabilities significantly. Recent earnings revealed a slight decline in sales to US$484.18 million for the year ended March 31, 2025, while losses have narrowed compared to the previous year. The company anticipates lower first-quarter revenue due to reduced marketing efforts amid uncertain macro conditions. Click here and access our complete financial health analysis report to understand the dynamics of BARK. Learn about BARK's future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Seritage Growth Properties is a company focused on the ownership, development, redevelopment, management, sale and leasing of diversified retail and mixed-use properties across the United States with a market cap of approximately $165.59 million. Operations: The company's revenue segment primarily involves real estate properties, which generated -$3.41 million. Market Cap: $165.59M Seritage Growth Properties, with a market cap of US$165.59 million, is navigating the complexities of penny stocks in the real estate sector. Despite ongoing unprofitability and declining earnings over five years, its short-term assets of US$123.1 million exceed short-term liabilities significantly but fall short against long-term liabilities of US$240 million. The company has reduced its debt substantially from 157.9% to 62.8% over five years and recently made a voluntary prepayment on its term loan facility, reducing annual interest expenses by approximately US$99.4 million since December 2021 while pursuing a strategic Plan of Sale reducing its portfolio to 15 assets from approximately 160 since March 2022. Click to explore a detailed breakdown of our findings in Seritage Growth Properties' financial health report. Review our historical performance report to gain insights into Seritage Growth Properties' track record. Investigate our full lineup of 449 US Penny Stocks right here. Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NAUT BARK and SRG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
